Progress in Dermatology and Venereology in 2023 as Reflected in the Journal of the European Academy of Dermatology and Venereology
December 2023
in “
JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology
”
New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide → 
Studysummary This study found that among melanoma patients in a real-world setting, adjuvant anti-PD-1 antibodies and BRAF/MEK inhibitors were associated with a recurrence-free survival of 78.1% and 86.5% respectively after 12 months.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
In 2023, the Journal of the European Academy of Dermatology and Venereology highlighted significant advancements in dermatology and venereology. Key studies included a multicentric study on adjuvant melanoma treatment with 1,194 patients showing high recurrence-free survival rates, and a Dutch study on Mohs Micrographic Surgery for basal cell carcinoma in older adults, emphasizing the impact of general morbidity on survival. Other notable research covered the efficacy of a topical mTOR inhibitor for facial angiofibromas, new expert recommendations for vitiligo management, and the development of new treatments for atopic dermatitis and pustular psoriasis. A systematic review on alopecia areata revealed a 75% reduction in quality of life for patients. The journal maintained a high impact factor of 9.2 and introduced three theme issues on melanoma, hair, and vitiligo.
